Molecular Mechanisms of Targeted Treatments and Immunotherapies for Solid Tumours

Over the course the first morning, Elaine guides you through the scientific concepts that underpin many of the most used targeted cancer treatments for solid tumours.

Elaine begins by describing what we can and can’t target, and the mechanisms of action of monoclonal antibodies and small molecules that block kinases. She then looks at the many treatments that block growth factor controlled signalling pathways. Finally, she turns her attention to other targets and to various biomarker tests to select the right approach for each patient.

On the second morning the focus is on cancer’s relationship with the immune system, and how this knowledge is being used to improve the outlook of people with many different cancer types. Checkpoint inhibitors (e.g. nivolumab, pembrolizumab) will take centre-stage.

Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine’s other courses
£50 per morning
To book, contact: or book online
View a PDF of the programme